Request Demo
Last update 06 Jun 2026
Recombinant Fc-glycosylated anti-CD20 monoclonal antibody(Bio-Thera Solutions, Ltd.)
Last update 06 Jun 2026
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms BAT 4306F, BAT-4306F, BAT4306F |
Target |
Action inhibitors |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 9699891H
Sequence Code 17734482L
Related
3
Clinical Trials associated with Recombinant Fc-glycosylated anti-CD20 monoclonal antibody(Bio-Thera Solutions, Ltd.)CTR20181568
一项评价BAT4306F注射液在复发/难治CD20阳性B细胞性非霍奇金淋巴瘤患者中的安全性、耐受性和药代动力学的I期临床研究
[Translation] A Phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of BAT4306F injection in patients with relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma
NCT04152148
A Phase I Clinical Trial of BAT4306F (for Injection) on Safety, Tolerability and Pharmacokinetics for Patients With CD20-positive, B-cell Non-Hodgkin's Lymphoma
ChiCTR1800018900
A Phase I Clinical Trial of BAT4306F (for injection) on Safety, Tolerability and Pharmacokinetics for Patients with CD20-positive, B-cell non-Hodgkin's lymphoma
100 Clinical Results associated with Recombinant Fc-glycosylated anti-CD20 monoclonal antibody(Bio-Thera Solutions, Ltd.)
Login to view more data
100 Translational Medicine associated with Recombinant Fc-glycosylated anti-CD20 monoclonal antibody(Bio-Thera Solutions, Ltd.)
Login to view more data
100 Patents (Medical) associated with Recombinant Fc-glycosylated anti-CD20 monoclonal antibody(Bio-Thera Solutions, Ltd.)
Login to view more data
100 Deals associated with Recombinant Fc-glycosylated anti-CD20 monoclonal antibody(Bio-Thera Solutions, Ltd.)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Recombinant Fc-glycosylated anti-CD20 monoclonal antibody(Bio-Thera Solutions, Ltd.) | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Phase 1 | China | 25 Oct 2018 | |
| Refractory Mature B-Cell Non-Hodgkin Lymphoma | Phase 1 | China | 25 Oct 2018 | |
| B-cell lymphoma refractory | Phase 1 | China | 06 Mar 2018 | |
| CD20 Positive B-Cell Non-Hodgkin Lymphoma | Phase 1 | China | 06 Mar 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free